pembrolizumab


( Last Updated : May 24, 2022)
Generic Name:
pembrolizumab
Project Status:
Active
Therapeutic Area:
Renal cell carcinoma, adjuvant
Manufacturer:
Merck Canada Inc.
Brand Name:
Keytruda
Project Line:
Reimbursement Review
Project Number:
PC0273-000
Tumour Type:
Genitourinary
NOC Status at Filing:
Pre NOC

Details


Manufacturer Requested Reimbursement Criteria1:
Adjuvant treatment of adult patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
Submission Type:
Initial
Fee Schedule:
Schedule A
Tumour Type:
Genitourinary
Indications:
Adjuvant treatment of adult patients with RCC at intermediate-high or high risk of recurrence following nephrectomy, or following nephrectomy and resection of metastatic lesions.
  1. The requested reimbursement criteria are provided by the applicant and do not necessarily reflect the views of CADTH. Reimbursement criteria from CADTH will be documented in the final recommendation, if applicable.

Key Milestones2

Call for patient/clinician input open02-Feb-22
Call for patient/clinician input closed25-Mar-22
Clarification:

- Patient input submission received from Kidney Cancer Canada

Submission received03-Mar-22
Submission accepted17-Mar-22
Review initiated21-Mar-22
Draft CADTH review report(s) provided to sponsor for comment08-Jun-22
Deadline for sponsors comments17-Jun-22
CADTH review report(s) and responses to comments provided to sponsor28-Jul-22
Expert committee meeting (initial)10-Aug-22